Is Opthea Ltd halal to invest in?

According to Musaffa's Shariah screening methodology, Opthea Ltd (OPT.AX) is currently classified as DOUBTFUL as of April 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Opthea Ltd a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Opthea Ltd using these criteria to determine its compliance status.

Can Muslims buy shares of Opthea Ltd?

Muslim investors may consider investing in Opthea Ltd if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Opthea Ltd classified as DOUBTFUL?

Musaffa determines the Shariah status of Opthea Ltd by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Opthea Ltd updated?

The Shariah compliance status of Opthea Ltd may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Opthea Ltd become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Opthea Ltd?

You can check the latest Shariah compliance status of Opthea Ltd on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

OPT.AX Shariah Compliance

Screening Methodology: AAOIFI

DOUBTFUL

Last Updated: April 27, 2026

Report Source: 2026 2nd Quarter Report

Opthea Ltd. Stock Analysis OPT.AX

Australia Health Care Small Cap Report: Q2, 2026

Opthea Ltd. is a clinical stage biopharmaceutical company, which engages in the development and research of novel therapeutic products based on targeting Vascular Endothelial Growth Factors. The company is headquartered in Melbourne, Victoria. The company is engaged in developing novel therapies to treat vision-threatening eye diseases, like wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate in Phase 3 development, sozinibercept, is a first-in-class VEGF-C/D trap inhibitor being evaluated in combination with standard-of-care anti-VEGF-A therapies to deliver superior vision to wet AMD patients. The company has initiated two pivotal Phase 3 clinical trials, COAST (Combination OPT-302 with Aflibercept Study) and ShORe (Study of OPT-302 in combination with Ranibizumab), in treatment-naive patients with wet AMD to evaluate the efficacy and safety of sozinibercept in combination with anti-VEGF-A therapies compared to anti-VEGF-A monotherapy. The company is advancing its clinical development program of sozinibercept in DME as well as investigating the feasibility of a co-formulation of sozinibercept with a VEGF-A inhibitor.

Key Statistics of Opthea Ltd (OPT.AX)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

AUD0.60AUD0.61

Today's Open

AUD0.60

Volume

2.13M

P/E Ratio (TTM)

52 Week Range

AUD0.60AUD0.62

Market Cap

820.79M

Avg. Volume

2.83M

Dividend Yield

Financial Metrics & Statements of Opthea Ltd (OPT.AX)

FAQ's for Opthea Ltd (OPT.AX)

According to Musaffa’s Shariah screening methodology, Opthea Ltd (OPT.AX) is currently classified as DOUBTFUL as of April 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.